Almirall launches Klisyri
Almirall is introducing Klisyri (tirbanibulin), for the topical treatment of actinic keratosis of the face and scalp.
Klisyri is a novel, topical, first-in-class microtubule inhibitor that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), and proven efficacy and safety profile. AK is the second most common diagnosis made by dermatologists in the United States.
It is estimated that more than 40 million Americans develop AKs each year.
Ayman Grada, head of R&D and medical affairs at Almirall U.S. said that the incidence of actinic keratosis has been increasing, including in younger adults. "Patients may prefer a treatment option with a short duration and proven safety and tolerability profile. The data for Klisyri offers this, as well as demonstrating efficacy for both face and scalp actinic keratoses."
"The U.S. launch of Klisyri marks another important milestone for Almirall toward our goal to be a leader in the field of dermatology and deliver new, innovative and effective treatment options," said Pablo Alvarez, president and general manager of Almirall U.S. "We are committed to providing patients with affordable access to our medications, and we have a copay card and a network of pharmacies covering the country to support this. We are excited to be able to offer this novel treatment option for dermatologists and their patients."
"Klisyri will help address unmet needs for many AK patients," said George Martin, a world-renowned expert in actinic keratosis and skin cancer. "Early diagnosis and a safe and highly effective topical for treatment of actinic keratosis is critical. Patients with actinic keratoses are at higher risk for developing non-melanoma skin cancer. Actinic keratosis can progress into squamous cell carcinoma, a common and sometimes invasive and deadly form of skin cancer."